23 clinical trials found.
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Study 849-001 is a multi-center, Phase 1/2, multiple expansion cohort trial evaluating the safety, PK, metabolites, PD and clinical activity/efficacy of MRTX849 in ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study is a trial to test the tolerability, side effects, and early effectiveness of the drug AZD0022 in patients with advanced tumors that have ...
Phase
TRIAL ROLE: Sub Investigator
-
A multicenter open label Phase 2 study to evaluate the efficacy and saftey of Sutetnib maleate capsule in locally advanced or metastatic NSCLC
This study is for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. The main goal is to see if ...
Phase
TRIAL ROLE: Sub Investigator
-
A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors
This study will test a new drug called LY4170156, an antibody drug conjugate (ADC) to see how it works in the body, and if it ...
Phase
TRIAL ROLE: Sub Investigator
-
An open-label phase I dose escalation expansion study of MGY825 in adult patients with advanced non-small cell lung cancer
This study wants to figure out if a new medicine called MGY825 is safe and helpful for patients with advanced non-small cell lung cancer. They ...
Phase
TRIAL ROLE: Sub Investigator
-
NVL-520-01: A Phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced NSCLC and other solid tumors (ARROS-1).
You can participate in this study if you are diagnosed with advanced non-small cell lung cancer, and other advanced solid cancers. The purpose of this ...
Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors
This is a multicenter, non-randomized, open-label, multiple-dose, first in human (FIH) study. The study consists of two parts: Part 1 adopts an accelerated titration at ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)Phase
TRIAL ROLE: Sub Investigator
-
A Master Protocol for the Multi-Cohort Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
This master protocol is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies ...Phase
TRIAL ROLE: Sub Investigator
